Quick Takeaways
- VANGUARD CAPITAL MANAGEMENT LLC filed SCHEDULE 13G for Viking Therapeutics Inc Common Stock (VKTX).
- Disclosed ownership: 5.1%.
- Date of event: 31 Mar 2026.
VANGUARD CAPITAL MANAGEMENT LLC - 31 Mar 2026 SCHEDULE 13G Report for Viking Therapeutics Inc Common Stock (VKTX)
- Filing Manager
- VANGUARD CAPITAL MANAGEMENT LLC
- Reporting Manager
- Vanguard Capital Management
- Security
- Viking Therapeutics Inc Common Stock
- Symbol
- VKTX
- Shares outstanding
- 115,694,154 shares
- Disclosed Ownership
- 5,877,263 shares
- Ownership
- 5.1%
- Form type
- SCHEDULE 13G
- Filing time
- 30 Apr 2026, 14:21:51 UTC
- Date of event
- 31 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD CAPITAL MANAGEMENT LLC disclosed 5.1% ownership in Viking Therapeutics Inc Common Stock (VKTX) on 31 Mar 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 30 Apr 2026, 14:21.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Vanguard Capital Management | 5.1% | 5,877,263 | 864,761 | 0 | Ashley Grim | Head of Global Fund Administration |